DK2137180T3 - Dibenzo[B,F][1,4]oxazapinforbindelser - Google Patents

Dibenzo[B,F][1,4]oxazapinforbindelser

Info

Publication number: DK2137180T3
Authority: DK; Denmark
Prior art keywords: schizophrenia; compounds; depression; psychotic; disorders
Prior art date: 2007-03-15

Application number

DK08732129.5T

Other languages

English (en)

Inventor

Cyrus Becker

Courtney Rubens

Jason Adams

Pascal Druzgala

Monica Palme

Original Assignee

Andaman Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-15

Filing date

2008-03-13

Publication date

2012-07-02

2008-03-13 Application filed by Andaman Therapeutics Inc filed Critical Andaman Therapeutics Inc

2012-07-02 Application granted granted Critical

2012-07-02 Publication of DK2137180T3 publication Critical patent/DK2137180T3/da

Links

UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
201000000980 schizophrenia Diseases 0.000 abstract 3
208000028017 Psychotic disease Diseases 0.000 abstract 2
206010003805 Autism Diseases 0.000 abstract 1
208000020706 Autistic disease Diseases 0.000 abstract 1
208000020925 Bipolar disease Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
206010036069 Polydipsia psychogenic Diseases 0.000 abstract 1
206010039987 Senile psychosis Diseases 0.000 abstract 1
208000028810 Shared psychotic disease Diseases 0.000 abstract 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 abstract 1
208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000024714 major depressive disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000030459 obsessive-compulsive personality disease Diseases 0.000 abstract 1
208000007656 osteochondritis dissecans Diseases 0.000 abstract 1
208000000231 psychogenic polydipsia Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK08732129.5T 2007-03-15 2008-03-13 Dibenzo[B,F][1,4]oxazapinforbindelser DK2137180T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89504607P	2007-03-15	2007-03-15
PCT/US2008/056866 WO2008112900A1 (en)	2007-03-15	2008-03-13	Dibenzo[b,f][1,4]oxazapine compounds

Publications (1)

Publication Number	Publication Date
DK2137180T3 true DK2137180T3 (da)	2012-07-02

Family

ID=39472572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08732129.5T DK2137180T3 (da)	2007-03-15	2008-03-13	Dibenzo[B,F][1,4]oxazapinforbindelser

Country Status (17)

Country	Link
US (2)	US8093237B2 (da)
EP (1)	EP2137180B1 (da)
JP (1)	JP5421787B2 (da)
KR (1)	KR101521951B1 (da)
CN (2)	CN101641350B (da)
AT (1)	ATE548367T1 (da)
AU (1)	AU2008225014B2 (da)
BR (1)	BRPI0808828A8 (da)
CA (1)	CA2678897C (da)
DK (1)	DK2137180T3 (da)
ES (1)	ES2384036T3 (da)
IL (1)	IL200250A (da)
MX (1)	MX2009009535A (da)
RU (1)	RU2469033C2 (da)
TW (1)	TWI421079B (da)
WO (1)	WO2008112900A1 (da)
ZA (1)	ZA200906573B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012283035B2 (en) *	2011-07-08	2015-07-30	Eli Lilly & Company	(thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT2A antagonists
CN106749219A (zh) *	2015-11-20	2017-05-31	江苏恩华药业股份有限公司	一种内酰胺类衍生物及其应用
US11649218B2 (en)	2018-03-09	2023-05-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same
WO2021119183A1 (en)	2019-12-13	2021-06-17	712 North, Inc.	Tricyclic compounds with oma1/opa1 modulatory properties
EP4416133A1 (en) *	2021-10-11	2024-08-21	Baylor College of Medicine	G-protein-coupled receptor regulators and methods of use thereof
TWI820605B (zh) *	2022-02-18	2023-11-01	國立臺灣大學	抗菌化合物、其製備方法及其用途
CN117164526A (zh) *	2022-05-27	2023-12-05	苏州泽璟生物制药股份有限公司	2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA979441A (en) *	1967-02-27	1975-12-09	American Cyanamid Company	11-(piperazinyl) dibenz (b,f) (1,4) oxazepines and analogous thiazepines
US3683084A (en) *	1969-02-06	1972-08-08	Jean Schmutz	Basically substituted heterocycles as anti-emetics
DE4127849A1 (de) *	1991-08-22	1993-02-25	Merck Patent Gmbh	Benzodioxanderivate
US5602124A (en) *	1994-12-12	1997-02-11	Allelix Biopharmaceuticals, Inc.	5-HT2 receptor ligands
IL117798A (en) *	1995-04-07	2001-11-25	Schering Plough Corp	Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
JPH0940662A (ja) *	1995-05-24	1997-02-10	Kyowa Hakko Kogyo Co Ltd	三環式化合物
CA2479932A1 (en)	2002-03-28	2003-10-09	Eli Lilly And Company	Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
ATE361289T1 (de)	2002-08-05	2007-05-15	Lilly Co Eli	Piperazinsubstituierte arylbenzodiazepine
JP2006510697A (ja)	2002-12-20	2006-03-30	ビーエーエスエフ　アクチェンゲゼルシャフト	殺虫性ジベンゾ（ヘテロ）アゼピン誘導体
WO2005026177A1 (en) *	2003-09-09	2005-03-24	Eli Lilly And Company	Substituted piperazines of azepines, oxazepines, and thiazepines
PT1696931E (pt) *	2003-12-22	2009-06-12	Acadia Pharm Inc	Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
EP1804804B1 (en) *	2004-09-21	2012-01-25	Hypnion, Inc.	3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS

2008
- 2008-03-13 AU AU2008225014A patent/AU2008225014B2/en not_active Ceased
- 2008-03-13 RU RU2009138039/04A patent/RU2469033C2/ru not_active IP Right Cessation
- 2008-03-13 CN CN2008800085093A patent/CN101641350B/zh not_active Expired - Fee Related
- 2008-03-13 EP EP08732129A patent/EP2137180B1/en not_active Not-in-force
- 2008-03-13 US US12/047,858 patent/US8093237B2/en not_active Expired - Fee Related
- 2008-03-13 WO PCT/US2008/056866 patent/WO2008112900A1/en not_active Ceased
- 2008-03-13 KR KR1020097021464A patent/KR101521951B1/ko not_active Expired - Fee Related
- 2008-03-13 CN CN2012103913667A patent/CN103214473A/zh active Pending
- 2008-03-13 ES ES08732129T patent/ES2384036T3/es active Active
- 2008-03-13 JP JP2009553781A patent/JP5421787B2/ja not_active Expired - Fee Related
- 2008-03-13 AT AT08732129T patent/ATE548367T1/de active
- 2008-03-13 MX MX2009009535A patent/MX2009009535A/es active IP Right Grant
- 2008-03-13 CA CA2678897A patent/CA2678897C/en not_active Expired - Fee Related
- 2008-03-13 DK DK08732129.5T patent/DK2137180T3/da active
- 2008-03-13 BR BRPI0808828A patent/BRPI0808828A8/pt not_active IP Right Cessation
- 2008-03-14 TW TW097109258A patent/TWI421079B/zh not_active IP Right Cessation
2009
- 2009-08-05 IL IL200250A patent/IL200250A/en not_active IP Right Cessation
- 2009-09-21 ZA ZA2009/06573A patent/ZA200906573B/en unknown
2011
- 2011-12-12 US US13/323,183 patent/US20120178738A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2137180A1 (en)	2009-12-30
BRPI0808828A2 (pt)	2017-05-02
WO2008112900A1 (en)	2008-09-18
US20120178738A1 (en)	2012-07-12
US8093237B2 (en)	2012-01-10
US20080255088A1 (en)	2008-10-16
IL200250A0 (en)	2010-04-29
AU2008225014A1 (en)	2008-09-18
AU2008225014B2 (en)	2014-12-11
MX2009009535A (es)	2009-09-16
TWI421079B (zh)	2014-01-01
RU2009138039A (ru)	2011-04-20
ES2384036T9 (es)	2013-10-14
CN101641350A (zh)	2010-02-03
TW200904449A (en)	2009-02-01
BRPI0808828A8 (pt)	2017-11-28
CN101641350B (zh)	2012-11-28
ATE548367T1 (de)	2012-03-15
RU2469033C2 (ru)	2012-12-10
CN103214473A (zh)	2013-07-24
CA2678897A1 (en)	2008-09-18
ZA200906573B (en)	2011-11-30
EP2137180B1 (en)	2012-03-07
JP2010521486A (ja)	2010-06-24
KR101521951B1 (ko)	2015-05-20
IL200250A (en)	2014-12-31
KR20090119999A (ko)	2009-11-23
CA2678897C (en)	2015-10-20
ES2384036T3 (es)	2012-06-28
JP5421787B2 (ja)	2014-02-19

Publication	Publication Date	Title
ZA200906573B (en)	2011-11-30	Dibenzo[1,4]oxazapine compounds
MA35285B1 (fr)	2014-07-03	Indazoles
NO20090166L (no)	2009-03-12	Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
PH12012501122A1 (en)	2012-10-29	Pteridinones as inhibitors of polo-like kinase
CY1119326T1 (el)	2018-02-14	Φαινυλο-3-αζα-δικυκλο[3.1.0]εξ-3-υλο-μεθανονες και η χρηση αυτων ως φαρμακο
TW201129562A (en)	2011-09-01	Iminothiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2010007683A (es)	2010-10-25	Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
NO20090755L (no)	2009-03-09	Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
MY167135A (en)	2018-08-13	Fused heterocyclic derivatives and methods of use
MX2009011830A (es)	2009-11-13	Compuestos amino-heterociclicos.
CY1117830T1 (el)	2017-05-17	Υποκατεστημενα παραγωγα τρικυκλικων οξεων ως αγωνιστες του υποδοχεα s1p1 χρησιμα στην αγωγη αυτοανοσων και φλεγμονοδων διαταραχων
MX2009013885A (es)	2010-01-27	Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico.
MX2010001486A (es)	2010-03-01	Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
NO20084516L (no)	2009-01-13	Terfenylderivater for behandling av alzheimers sykdom
MX350862B (es)	2017-09-19	Acidos de piperidinil naftilacetico.
MA32137B1 (fr)	2011-03-01	Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour leur fabrication
IL205045A (en)	2015-08-31	Piperidinyl and piperazine derivatives, preparations containing them and their uses
MX2009010727A (es)	2009-10-26	Heterociclos como antagonistas de orexina.
NZ593279A (en)	2013-03-28	Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
TW200735878A (en)	2007-10-01	Pharmaceutical compositions
EA200870492A1 (ru)	2009-04-28	N-оксиды производных пиридилметилпиперазина и - пиперидина
UA86873C2 (en)	2009-05-25	SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
ATE407126T1 (de)	2008-09-15	Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on
DE602006007483D1 (da)	2009-08-06
BRPI0606730A2 (pt)	2009-07-14	derivados de fenil metanona 2,5-di-substituìdos como inibidores do transportador de glicina 1 (glyt-1) para o tratamento de distúbios neurológicos e neuropsiquiátricos